AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme





Fill the form to download Workflow Comparison Study with AQUIOS CL Flow Cytometer

London Health Sciences Centre (LHSC) Workflow Comparison Study with the AQUIOS CL Flow Cytometer



Innovation In CD4 Testing

UNAIDS 90-90-90 Initiative

HIV Advanced Disease Management ​

More than a third of people starting ART have advanced HIV disease, and an increasing number of patients develop an advanced HIV after disengaging from care.
HIV Diagnosis Becomes up to Four Times Faster Thanks to This Invention

HIV Diagnosis Becomes up to Four Times Faster Thanks to This Invention

HIV/AIDS Africa’s most vulnerable can benefit from simple test which monitors disease progression, enabling the comprehensive treatment programs.
The AQUIOS  CL flow cytometer has been accepted by the WHO Prequalification of In Vitro Diagnostics Program

AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme

The AQUIOS CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program.
London Health Sciences Centre (LHSC) Workflow Comparison Study With The AQUIOS CL Flow Cytometer

Case Study: London Health Sciences Centre (LHSC)

AQUIOS CL provides faster times to first result, faster turnaround times and faster total elapsed times, with fewer total steps and less hands-on time.


**These reagents provide identification and enumeration of the following lymphocyte subset populations:

  • total CD3+, CD3+CD4+,CD3+CD8+, CD3+CD4+/CD3+CD8+ (ratio only) lymphocyte percentages and absolute counts;
  • CD45+ absolute count; and
  • CD45+ Low SS (lymphocytes) percentage and absolute count.